Gold
EW4C: Sep. 25 (Fri), 12:00-13:00/ Room C (1F)
| Address | 5F, (Seoul Square) 416, Hangang-daero, Jung-gu, Seoul, 04637, Korea | ||
|---|---|---|---|
| Telephone | +82-2-2626-5700 | Fax | +82-2-2626-5705 |
| Website | www.qiagen.com | ||
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2020, QIAGEN employed approximately 5,100 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
QFT-Plus is an improved version of the industry-leading IGRA for TB detection. It is now optimized with innovative tuberculosis-specific antigens that elicit both CD8+ and CD4+ T cell responses – enabling a more accurate assessment of cell-mediated immune response to TB infection for additional clinical information.
QIAGEN's premier sample-to-result workflow solution comprises the QIAsymphony SP for sample preparation, the QIAsymphony AS for assay setup, and a broad range of ready-to-use assays on the Rotor-Gene Q real-time PCR cycler. QIAsymphony RGQ can save you time by processing up to 96 samples, from sample to result, in one integrated run.
QuantiFERON®-CMV test is CMV-specific immune monitoring test and this monitoring immune levels gives you more clinical evidence to manage patients posttransplant.
